CD20 protein
E261827
CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
All labels observed (5)
| Label | Occurrences |
|---|---|
| CD20 antigen | 3 |
| B‑lymphocyte antigen CD20 | 1 |
| CD20 | 1 |
| CD20 protein canonical | 1 |
| LEU‑16 antigen | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2371007 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CD20 protein Context triple: [Rituxan, targets, CD20 protein]
-
A.
Bruton tyrosine kinase
Bruton tyrosine kinase is a key signaling enzyme in B cells that plays a crucial role in their development and function and is a major therapeutic target in certain blood cancers and autoimmune diseases.
-
B.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
-
C.
programmed death-ligand 1
Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
CD4+ T cells
CD4+ T cells are a subset of immune cells that coordinate and regulate the body’s adaptive immune response, playing a central role in defending against infections.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: CD20 protein Target entity description: CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
-
A.
Bruton tyrosine kinase
Bruton tyrosine kinase is a key signaling enzyme in B cells that plays a crucial role in their development and function and is a major therapeutic target in certain blood cancers and autoimmune diseases.
-
B.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
-
C.
programmed death-ligand 1
Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
CD4+ T cells
CD4+ T cells are a subset of immune cells that coordinate and regulate the body’s adaptive immune response, playing a central role in defending against infections.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
B‑cell marker
ⓘ
cell surface antigen ⓘ drug target ⓘ membrane protein ⓘ |
| alternativeName |
B1 antigen
ⓘ
Bp35 ⓘ CD20 protein ⓘ
surface form:
B‑lymphocyte antigen CD20
CD20 protein ⓘ
surface form:
LEU‑16 antigen
|
| belongsToFamily | membrane‑spanning 4‑domains subfamily A (MS4A) ⓘ |
| biologicalProcess |
B‑cell activation
ⓘ
B‑cell differentiation ⓘ B‑cell proliferation ⓘ regulation of calcium ion transport ⓘ |
| cellularLocation | plasma membrane ⓘ |
| encodedBy | MS4A1 gene ⓘ |
| expressedIn |
human immune system
ⓘ
lymph nodes ⓘ peripheral blood B cells ⓘ spleen B cells ⓘ |
| foundIn |
B lymphocyte membrane
ⓘ
mature B cells ⓘ pre‑B cells ⓘ |
| hasTransmembraneDomains | 4 ⓘ |
| molecularFunction |
B‑cell receptor signaling modulator
ⓘ
calcium ion channel regulator activity ⓘ |
| notExpressedIn |
hematopoietic stem cells
ⓘ
normal plasma cells ⓘ pro‑B cells ⓘ |
| organism | Homo sapiens ⓘ |
| postTranslationalModification | glycosylation ⓘ |
| recognizedBy | anti‑CD20 monoclonal antibodies ⓘ |
| targetOf |
mosunetuzumab (bispecific antibody component)
ⓘ
Rituxan ⓘ
surface form:
obinutuzumab
ocrelizumab ⓘ Ofatumumab ⓘ
surface form:
ofatumumab
Ofatumumab ⓘ
surface form:
ofatumumab (autoimmune indications)
Rituxan ⓘ
surface form:
rituximab
|
| therapeuticArea |
B‑cell non‑Hodgkin lymphoma
ⓘ
chronic lymphocytic leukemia ⓘ granulomatosis with polyangiitis ⓘ microscopic polyangiitis ⓘ multiple sclerosis ⓘ pemphigus vulgaris ⓘ rheumatoid arthritis ⓘ |
| topology | multi‑pass transmembrane protein ⓘ |
| usedAs |
diagnostic marker for B‑cell leukemias
ⓘ
diagnostic marker for B‑cell lymphomas ⓘ |
| usedIn |
immunohistochemistry of lymphoid tissues
ⓘ
immunophenotyping of B cells by flow cytometry ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: CD20 protein Description of subject: CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
Referenced by (7)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
B‑lymphocyte antigen CD20
this entity surface form:
LEU‑16 antigen
this entity surface form:
CD20